Transient extreme insulin resistance in shock during diabetic ketoacidosis.
Transient extreme insulin resistance was encountered during an episode of diabetic ketoacidosis (DKA) in an insulin-treated diabetic patient. On admission, the plasma glucose level was 1241 mg dl-1 and arterial blood pH 6.895 with HCO3- 4.7 mEql-1. An intravenous bolus injection of 20 units, followed by continuous infusion of 20 units h-1 of short-acting regular human insulin, was instituted. Ischemic myocardial changes were noted on the initial electrocardiogram, therefore fluid replacement was limited to 1,000 ml of 0.9% saline solution in the first hour. As the plasma glucose level declined by only 203 mg dl-1 (41 mg dl-1 h-1) in the first 5 h, the insulin dose was doubled every 2 h. At hour 4, the patient developed circulatory shock which required vasopressor support and respiratory assistance. A plasma glucose level of 300 mg dl-1 was not achieved until the total dosage of insulin amounted to 91,580 units at hour 25. Insulin resistance was not observed from that point on. The patient had neither insulin antibodies nor anti-insulin receptor antibodies in serologic testing. The insulin binding characteristics of the patient's erythrocytes were similar to those from healthy controls both with and without experimental acidosis and with a high level of beta-hydroxybutyrate. Among multiple potential factors, the severe shock associated with DKA has been considered as a primary cause of the transient severe insulin resistance in this case.
Yokoyama
H
H
Diabetes Center, Tokyo Women's Medical College, Japan.
Wasada
T
T
Shimizu
Y
Y
Yoshino
H
H
Hasumi
S
S
Omori
Y
Y
D020155:3-Hydroxybutyric Acid; D058186:Acute Kidney Injury / Q000209:etiology; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D016883:Diabetic Ketoacidosis / Q000150:complications / Q000188:drug therapy*; D004912:Erythrocytes / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D006885:Hydroxybutyrates / Q000378:metabolism; D007262:Infusions, Intravenous; D007328:Insulin / Q000008:administration & dosage / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use*; D007333:Insulin Resistance; D007659:Ketones / Q000097:blood; D008297:Male; D017202:Myocardial Ischemia / Q000209:etiology; D011014:Pneumonia / Q000188:drug therapy / Q000209:etiology; D011972:Receptor, Insulin / Q000276:immunology / Q000378:metabolism; D012206:Rhabdomyolysis / Q000150:complications; D012769:Shock / Q000209:etiology*
D001786:Blood Glucose; D006885:Hydroxybutyrates; D007328:Insulin; D007659:Ketones; D011972:Receptor, Insulin; D020155:3-Hydroxybutyric Acid